Glucagon-like peptide-1 receptor agonist diminishes endothelial dysfunction in type 2 diabetic patients
https://doi.org/10.24884/1682-6655-2018-17-2-57-63
Abstract
Objective. To evaluate liraglutide (LIR) endothelial protective action. Material and methods. Type 2 diabetic patients with HbA1C 7.5-9.0 % had metformin (MET) dose titrated for 3 months. Patients with HbA1C less than 7.5 % comprised group 1 (MET), more than 7.5 % - group 2 (MET+LIR). Blood concentrations of tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), endothelin-1 (E) were evaluated at baseline, in 3, 6 and 9 months. Results. PAI-1 was increased in both groups and gradually decreased. T-PA was normal. E was primarily increased only in group 2. E was normal in group 1 in general, but enlarged with glycaemia increase. E decreased in group 2 with glycaemia improvement and worsening. Conclusions. Glycaemia control improvement decreases endothelial dysfunction. LIR improves vasomotor endothelial function, independently on its influence on glycaemia.
About the Authors
A. V. Simanenkova
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»
Russian Federation
Russian Federation
M. N. Makarova
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»
Russian Federation
Russian Federation
L. V. Vasina
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»; Federal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
M. I. Butomo
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»
Russian Federation
Russian Federation
S. V. Dora
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»
Russian Federation
Russian Federation
E. V. Shlyakhto
Federal State Budgetary Educational Institution of Higher Education «Pavlov First Saint Petersburg State Medical University»; Federal State Budgetary Institution «Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Adly AAM, Elbarbary NS, Ismail EAR et al. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic microvascular complications and carotid intima media thickness. J Diabetes Complications. 2014;28(3):340-347. doi: 10.1016/j.jdiacomp.2014.01.011.
2. Al-Hamodi Z, Ismail IS, Saif-Ali R et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 2011;18;10:23. doi: 10.1186/1475-2840-10-23.
3. Bao W, Aravindhan K, Alsaid H, et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6(8):e23570. doi: 10.1371/journal.pone.0023570.
4. Briyal S, Gulati A. Effect of liraglutide on oxidative stress and apoptosis in rats following focal cerebral ischemia. Critical Care Medicine. 2012;40(12):1-328. doi: 10.1097/01.ccm.0000424416.67430.bc.
5. Dokken BB, La Bonte LR, Davis-Gorman G, et al. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43(5):300-3005. doi: 10.1055/s-0031-1271777.
6. Gaspari T, Welungoda I, Widdop RE et al. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model. Diab Vasc Dis Res. 2013;10(4):353-60. doi: 10.1177/1479164113481817.
7. IDF Diabetes Atlas. 8-th edition. 2017. Available at: http://www.diabetesatlas.org/across-the-globe.html (accessed 15.03.2018).
8. Koska J. Incretins and preservation of endothelialfunction. Cardiovasc Hematol Agents Med Chem. 2012;10:295-308. doi: 10.2174/187152512803530289.
9. Li PC, Liu LF, Jou MJ et al. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016;17(1):37. doi:10.1186/s12868-016-0272-9.
10. Lonborg JL, Vejlstrup N, Kelbak H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491-9. doi: 10.1093/eurheartj/ehr309.
11. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975-983. doi: 10.2337/db08-1193.
12. Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98(5):408-13. doi: 10.1136/hrt.2010.219345.
13. Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes/Metabolism Reviews. 1998;14:171-175. doi: 10.1002/(SICI)1099-0895(199806)14:2.
14. Sato K, Kameda M, Yasuhara T et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci. 2013;14(11):21513-21524. doi: 10.3390/ijms141121513.
15. Schneider JG, Tilly N, Hierl T et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967-972. doi: 10.1016/S0895-7061(02)03060-1.
16. Shiraki A, Oyama J, Komoda H et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-a-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis. 2012;221(2):375-382. doi: 10.1016/j.atherosclerosis.2011.12.039.
17. Vicente MRV, Alameda C, Becerra A et al. Relationship between endothelin-1 levels in diabetics with and without microangiopathy and control subjects. Endocrine Abstracts. 2013;32:431. doi: 10.1530/endoabs.32.P431.
18. Zeravica R, Ilincic B, Cabarkapa V et al. Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;80(2):299-304. doi: 10.1016/j.diabres.2007.12.024.
19. Zhong Z-L, Chen S. Plasma Plasminogen Activator Inhibitor-1 Is Associated with End-Stage Proliferative Diabetic Retinopathy in the Northern Chinese Han Population. Exp Diabetes Res. 2012;2012:350852. doi: 10.1155/2012/350852.
Review
For citations:
Simanenkova A.V., Makarova M.N., Vasina L.V., Butomo M.I., Dora S.V., Shlyakhto E.V. Glucagon-like peptide-1 receptor agonist diminishes endothelial dysfunction in type 2 diabetic patients. Regional blood circulation and microcirculation. 2018;17(2):57-63. (In Russ.) https://doi.org/10.24884/1682-6655-2018-17-2-57-63
Views:
1201
Email this article 
